Office of Technology Commercialization
Office of Technology Commercialization

Georgetown’s Technology Pipeline

At Georgetown University, innovation thrives. Our Technology Pipeline showcases exciting technologies under development by industry partners who have licensed Georgetown’s discoveries and innovations. This pipeline represents examples of our groundbreaking research being translated into real-world applications, highlighting the university’s commitment to collaboration and technological advancement across various sectors. 

A table titled "Therapeutics" displays the development pipeline for various medical innovations licensed from Georgetown University. The table is organized into columns: Licensee, Product, Indication, and a Visual Status Tracker showing progress through Pre-clinical, Phase I, Phase II, Phase III, NDA/BLA, and Market stages. The data entries include: Diviner Therapeutics, LLC: Small Molecule Inhibitor G0133 for Pancreatic Cancer (Pre-clinical). J-Pharma Co. LTD: Small Molecule Inhibitor LAT1 Inhibitor for MS and Neurological Diseases (Pre-clinical). Cantex Pharmaceuticals, Inc.: RAGE Inhibitor for Cancer-related Cognitive Decline (Phase II). Xicunio Pharmaceuticals, LLC: Antibody Drug Conjugate for Cancer (Pre-clinical). CCKR: Novel use of CCK receptor inhibitors for Pancreatic Cancer, HCC, NASH, and Pancreatitis (Phase II). SynerGene Therapeutics, Inc.: Targeted liposomal delivery system (SGT-53) for advanced solid tumors (Phase II). Dubliner Therapeutics, Inc.: Small Molecule Inhibitor for Neurodegenerative diseases (Pre-clinical).

Alt Text A table titled "Diagnostic/Device Products" illustrates the pipeline for medical hardware and testing technologies licensed from Georgetown University. The table includes columns for Licensee, Product, Indication, and a Visual Status Tracker with stages for Prototype, In Development, and Market. The specific data entries are: A Medtech Company: Listed with a "Medical Device" product for an unspecified indication; its status is shown as being in the In Development stage. Shuttle Pharmaceuticals, Inc.: Developing a "Diagnostic test to predict the likelihood for success or failure of radiation treatment for individual prostate cancer patients" for the indication of Prostate Cancer. The status tracker indicates this is in the late In Development stage, nearing the Market phase. A Medtech Company: Listed with an "Antibody" product for the indication of Ewing's Sarcoma; its status is shown in the In Development stage.

A table titled "Consumer and Other Products" outlines various tools and educational materials licensed through Georgetown University. The table contains columns for Licensee, Product, Indication, and a Visual Status Tracker with stages for Product, In Development, and Market. The entries in this section include: STEMCELL Technologies, Inc.: Two products—"Conditioned Medium from 3T3-J2 irradiated feeder cells" and "Cell Media." Both are listed with the indication "Research Tool" and are shown as having reached the Market stage. Sage Publications Ltd.: "Educational material describing statistical and experimental tools to measure the effects of policies and interventions implemented on low- and middle-income countries." The indication is "Consumer Product For Education," and it is in the Market stage. NeuroCore Technologies, LLC: "An app to improve reasoning using a spatial scaffolding tool that allows users to create and drag tokens in order to solve reasoning problems." The indication is "Consumer Product," and it is in the Market stage. The Trauma Informed Academy®: "TI-MED is a research-based trauma-informed care training for healthcare workers who have patient contact." The indication is "Training Tool," and it is currently in the In Development stage.